Download PDF
Zentralbl Chir 2024; 149(01): 83-90
DOI: 10.1055/a-2241-0128
Übersicht

Palliative Systemtherapie des metastasierten Rektumkarzinoms

Palliative Treatment of Metastatic Rectal Cancer
Thomas Seufferlein
1   Klinik für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Deutschland (Ringgold ID: RIN27197)
,
Thomas Jens Ettrich
1   Klinik für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Deutschland (Ringgold ID: RIN27197)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die palliative Behandlung des metastasierten Rektumkarzinoms (mCRC) hat sich in den letzten Jahren durch neue Behandlungsstrategien wie Induktions- und Erhaltungstherapien, die Etablierung zielgerichteter Therapien und molekular definierte Therapien in bestimmten Untergruppen wie MSI-H-Patienten erheblich erweitert. Der folgende Artikel stellt evidenzbasiert therapeutische Optionen und Behandlungsalgorithmen vor.

Abstract

Palliative treatment of metastatic rectal cancer (mCRC) has developed considerably in recent years, with new therapeutic strategies such as induction and maintenance therapies, the establishment of targeted therapies and molecularly defined strategies in defined subgroups such as MSI-H-patients. The following article presents evidence based therapeutic options and algorithms.

Schlüsselwörter

Rektumkarzinom - Metastasen - Systemtherapie

Keywords

rectal cancer - metastases - systemic treatment


Publication History

Received: 13 October 2023

Accepted after revision: 30 December 2023

Article published online:
05 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Cervantes A, Adam R, Roselló S. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 10-32 DOI: 10.1016/j.annonc.2022.10.003. (PMID: 36307056)
    CrossrefPubMedGoogle Scholar
  • 2 Montagut C, Vidal J. Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer. N Engl J Med 2022; 386: 2330-2331 DOI: 10.1056/NEJMe2204625. (PMID: 35657319)
    CrossrefPubMedGoogle Scholar
  • 3 Mauri G, Vitiello PP, Sogari A. et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 2022; 127: 394-407 DOI: 10.1038/s41416-022-01769-8. (PMID: 35264786)
    CrossrefPubMedGoogle Scholar
  • 4 Watanabe J, Muro K, Shitara K. et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2023; 329: 1271-1282 DOI: 10.1001/jama.2023.4428.
    CrossrefPubMedGoogle Scholar
  • 5 Heinemann V, von Weikersthal LF, Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075 DOI: 10.1016/s1470-2045(14)70330-4.
    CrossrefPubMedGoogle Scholar
  • 6 Rossini D, Boccaccino A, Carullo M. et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer 2023; 184: 106-116 DOI: 10.1016/j.ejca.2023.02.006. (PMID: 36913832)
    CrossrefPubMedGoogle Scholar
  • 7 Loupakis F, Cremolini C, Masi G. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618 DOI: 10.1056/NEJMoa1403108.
    CrossrefPubMedGoogle Scholar
  • 8 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315 DOI: 10.1016/S1470-2045(15)00122-9.
    CrossrefPubMedGoogle Scholar
  • 9 Douillard JY, Oliner KS, Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England journal of medicine 2013; 369: 1023-1034 DOI: 10.1056/NEJMoa1305275. (PMID: 24024839)
    CrossrefPubMedGoogle Scholar
  • 10 Arnold D, Lueza B, Douillard JY. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials†. Ann Oncol 2017; 28: 1713-1729 DOI: 10.1093/annonc/mdx175.
    CrossrefPubMedGoogle Scholar
  • 11 Cremolini C, Antoniotti C, Stein A. et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol 2020; DOI: 10.1200/jco.20.01225. (PMID: 32816630)
    CrossrefPubMedGoogle Scholar
  • 12 Schwartzberg LS, Rivera F, Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247 DOI: 10.1200/JCO.2013.53.2473. (PMID: 24687833)
    CrossrefPubMedGoogle Scholar
  • 13 Stinzing Sea. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013, Amsterdam 2013
    PubMedGoogle Scholar
  • 14 Lenz H, Niedzwiecki D, Innocenti F. et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Onc 2014; 25: 1-41 DOI: 10.1093/annonc/mdu438. (PMID: 32598257)
    CrossrefPubMedGoogle Scholar
  • 15 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
    CrossrefPubMedGoogle Scholar
  • 16 Cunningham D, Lang I, Marcuello E. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085
    CrossrefPubMedGoogle Scholar
  • 17 Modest DP, Martens UM, Riera-Knorrenschild J. et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol 2019; 37: 3401-3411 DOI: 10.1200/JCO.19.01340. (PMID: 31609637)
    CrossrefPubMedGoogle Scholar
  • 18 Saltz LB, Clarke S, Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
    CrossrefPubMedGoogle Scholar
  • 19 André T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383: 2207-2218 DOI: 10.1056/NEJMoa2017699. (PMID: 33264544)
    CrossrefPubMedGoogle Scholar
  • 20 Simkens LH, van Tinteren H, May A. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852 DOI: 10.1016/S0140-6736(14)62004-3.
    CrossrefPubMedGoogle Scholar
  • 21 Hegewisch-Becker S, Graeven U, Lerchenmüller CA. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1355-1369 DOI: 10.1016/S1470-2045(15)00042-X.
    CrossrefPubMedGoogle Scholar
  • 22 Modest DP, Karthaus M, Frühauf S. et al. Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212). J Clin Oncol 2021; 39 (Suppl. 15) 3503-3503 DOI: 10.1200/JCO.2021.39.15_suppl.3503.
    CrossrefPubMedGoogle Scholar
  • 23 Giantonio BJ, Catalano PJ, Meropol NJ. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
    CrossrefPubMedGoogle Scholar
  • 24 Bennouna J, Sastre J, Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 DOI: 10.1016/S1470-2045(12)70477-1. (PMID: 23168366)
    CrossrefPubMedGoogle Scholar
  • 25 Tabernero J, Van Cutsem E, Lakomy R. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50: 320-331 DOI: 10.1016/j.ejca.2013.09.013.
    CrossrefPubMedGoogle Scholar
  • 26 Tabernero J, Yoshino T, Cohn AL. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508 DOI: 10.1016/S1470-2045(15)70127-0.
    CrossrefPubMedGoogle Scholar
  • 27 Kopetz S, Grothey A, Yaeger R. et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 2019; 381: 1632-1643 DOI: 10.1056/NEJMoa1908075. (PMID: 31566309)
    CrossrefPubMedGoogle Scholar
  • 28 André T, Lonardi S, Wong KYM. et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol 2022; 33: 1052-1060 DOI: 10.1016/j.annonc.2022.06.008. (PMID: 35764271)
    CrossrefPubMedGoogle Scholar
  • 29 Mayer RJ, Van Cutsem E, Falcone A. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919 DOI: 10.1056/NEJMoa1414325. (PMID: 25970050)
    CrossrefPubMedGoogle Scholar
  • 30 Pfeiffer P, Yilmaz M, Möller S. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21: 412-420 DOI: 10.1016/S1470-2045(19)30827-7. (PMID: 31999946)
    CrossrefPubMedGoogle Scholar
  • 31 Grothey A, Van Cutsem E, Sobrero A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312 DOI: 10.1016/s0140-6736(12)61900-x. (PMID: 23177514)
    CrossrefPubMedGoogle Scholar
  • 32 Dasari A, Lonardi S, Garcia-Carbonero R. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023; 402: 41-53
    CrossrefPubMedGoogle Scholar
  • 33 Fakih MG, Kopetz S, Kuboki Y. et al. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022; 23: 115-124
    CrossrefPubMedGoogle Scholar
  • 34 Fakih MG, Salvatore L, Esaki T. et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 389: 2125-2139
    CrossrefPubMedGoogle Scholar
  • 35 Yaeger R, Weiss J, Pelster MS. et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 388: 44-54 DOI: 10.1056/NEJMoa2212419. (PMID: 36546659)
    CrossrefPubMedGoogle Scholar
  • 36 Tosi F, Sartore-Bianchi A, Lonardi S. et al. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clin Colorectal Cancer 2020; 19: 256-262.e2 DOI: 10.1016/j.clcc.2020.06.009.
    CrossrefPubMedGoogle Scholar
  • 37 Yoshino T, Di Bartolomeo M, Raghav K. et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023; 14: 3332
    CrossrefPubMedGoogle Scholar
  • 38 Osterlund P, Kinos S, Pfeiffer P. et al. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine-or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open 2022; 7: 100427 DOI: 10.1016/j.esmoop.2022.100427.
    CrossrefPubMedGoogle Scholar
  • 39 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182-1191 DOI: 10.1016/s1470-2045(17)30422-9. (PMID: 28734759)
    CrossrefPubMedGoogle Scholar
  • 40 Antoniotti C, Rossini D, Pietrantonio F. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2022; 23: 876-887 DOI: 10.1016/s1470-2045(22)00274-1. (PMID: 35636444)
    CrossrefPubMedGoogle Scholar
  • 41 Moretto R, Rossini D, Catteau A. et al. Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. J Immunother Cancer 2023; 11: e006633 DOI: 10.1136/jitc-2022-006633.
    CrossrefPubMedGoogle Scholar
  • 42 Peeters M, Price TJ, Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713 DOI: 10.1200/JCO.2009.27.6055.
    CrossrefPubMedGoogle Scholar
  • 43 Overman MJ, Lonardi S, Wong KYM. et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018; 36: 773-779 DOI: 10.1200/jco.2017.76.9901.
    CrossrefPubMedGoogle Scholar
  • 44 Tabernero J, Grothey A, Van Cutsem E. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021; 39: 273-284 DOI: 10.1200/JCO.20.02088.
    CrossrefPubMedGoogle Scholar
  • 45 Fakih MG, Kopetz S, Kuboki Y. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022; 23: 115-124 DOI: 10.1016/S1470-2045(21)00605-7.
    CrossrefPubMedGoogle Scholar
  • 46 Sacher A, LoRusso P, Patel MR. et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389: 710-721 DOI: 10.1056/NEJMoa2303810.
    CrossrefPubMedGoogle Scholar
  • 47 Prager GW, Taieb J, Fakih M. et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 2023; 388: 1657-1667 DOI: 10.1056/NEJMoa2214963. (PMID: 37133585)
    CrossrefPubMedGoogle Scholar
  • 48 Suenaga M, Mizunuma N, Matsusaka S. et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015; 9: 3099-3108 DOI: 10.2147/dddt.S85567.
    CrossrefPubMedGoogle Scholar
  • 49 Cremolini C, Rossini D, Dell’Aquila E. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 2019; 5: 343-350 DOI: 10.1001/jamaoncol.2018.5080.
    CrossrefPubMedGoogle Scholar
  • 50 Martinelli E, Martini G, Famiglietti V. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol 2021; 7: 1529-1535 DOI: 10.1001/jamaoncol.2021.2915.
    CrossrefPubMedGoogle Scholar
  • 51 Dasari NA, Lonardi S, Garcia-Carbonero R. et al. LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann Oncol 2022; 33: 1391-1392 DOI: 10.1016/j.annonc.2022.08.021.
    CrossrefPubMedGoogle Scholar
  • 52 Siena S, Di Bartolomeo M, Raghav K. et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22: 779-789 DOI: 10.1016/s1470-2045(21)00086-3.
    CrossrefPubMedGoogle Scholar
  • 53 Shitara K, Muro K, Watanabe J. et al. Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. J Clin Oncol 2023; DOI: 10.1200/JCO.2023.41.4_suppl.11.
    CrossrefPubMedGoogle Scholar